Conducted at Comandante Faustino Perez Clinical-Surgical-Teaching Hospital in this western region of Cuba, the research aims at assessing the drug’s efficacy in reducing joint pain and inflammation.
According to the website www.radio26.cu, the study includes individuals who have suffered from chikungunya virus and have maintained joint symptoms for more than three months. Participants were selected based on their ages, ranging from 19 to 80 years old, and specific criteria were used to ensure greater effectiveness in the trial’s results.
The Jusvinza treatment consists of nine subcutaneous doses distributed over six weeks. Three consecutive doses are given in the first week; In the second phase, two doses are given, and from the third to the sixth phase, one dose per week, explained Yudisay Reyes, an oncology specialist and member of the Clinical Research Group at the CIGB (Center for Genetic Engineering and Biotechnology).
The treatment regimen can be given on an outpatient or inpatient basis, depending on the patient’s clinical condition and place of residence, especially for those living far from the Faustino Perez Hospital, she said.
The news outlet specifies that the trial includes 120 patients divided into two groups of 60: one group will receive Jusvinza drig in addition to conventional treatment, and the other will continue with standard therapy only.
jdt/ro/ads
